Trial reportThe New England journal of medicine2008
A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy.
Trial report in The New England journal of medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 177 papers, 19 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Clinical Trial of the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM)
A Multicenter Randomized Controlled Trial of Therapeutic Hypothermia Plus Magnesium Sulphate (MgSO4) Versus Therapeutic Hypothermia Plus Placebo in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy
Pharmacokinetics (PK)/Pharmacodynamics (PD) Modeling of Magnesium Sulfate In the Mother and Exposed Neonate
Who cites it
177 citing papers in PubMed, 19 syntheses or guidelines pooled it.
- Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus.The Cochrane database of systematic reviews · 2026Pooled it
- Persistent dysregulated inflammation in cerebral palsy: a systematic review.Pediatric research · 2026Pooled it
- Magnesium sulfate for fetal neuroprotection in preterm labor: an updated systematic review and meta-analysis of randomized controlled trials.Archives of gynecology and obstetrics · 2025Pooled it
- The uncanny valley effect in embodied conversational agents: a critical systematic review of attractiveness, anthropomorphism, and uncanniness.Frontiers in psychology · 2025Pooled it
- Magnesium sulfate for fetal neuroprotection in preterm pregnancy: a meta-analysis of randomized controlled trials.BMC pregnancy and childbirth · 2024Pooled it
- Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus.The Cochrane database of systematic reviews · 2024Pooled it
- Antenatal Magnesium Sulfate and adverse gastrointestinal outcomes in Preterm infants-a systematic review and meta-analysis.Journal of perinatology : official journal of the California Perinatal Association · 2023Pooled it
- Interventions to Reduce Severe Brain Injury Risk in Preterm Neonates: A Systematic Review and Meta-analysis.JAMA network open · 2023Pooled it
- A Systematic Review of Magnesium Sulfate for Perinatal Neuroprotection: What Have We Learnt From the Past Decade?Frontiers in neurology · 2020Pooled it
- Antenatal magnesium sulphate and adverse neonatal outcomes: A systematic review and meta-analysis.PLoS medicine · 2019Pooled it
- Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis.PLoS medicine · 2017Pooled it
- Effects and Safety of Magnesium Sulfate on Neuroprotection: A Meta-analysis Based on PRISMA Guidelines.Medicine · 2016Pooled it
- Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review.BMC pregnancy and childbirth · 2013Pooled it
- Magnesium sulphate for women at term for neuroprotection of the fetus.The Cochrane database of systematic reviews · 2013Pooled it
- Antenatal magnesium individual participant data international collaboration: assessing the benefits for babies using the best level of evidence (AMICABLE).Systematic reviews · 2012Pooled it
- Different magnesium sulphate regimens for neuroprotection of the fetus for women at risk of preterm birth.The Cochrane database of systematic reviews · 2012Pooled it
- Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis.Obstetrics and gynecology · 2009Pooled it
- Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis.American journal of obstetrics and gynecology · 2009Pooled it
- Reducing stillbirths: interventions during labour.BMC pregnancy and childbirth · 2009Pooled it
- Esophageal Versus Rectal Temperature Monitoring During Whole-Body Therapeutic Hypothermia for Hypoxic-Ischemic Encephalopathy: Association with Short- and Long-Term Outcomes.The Journal of pediatrics · 2024Trial
117 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
24 authors.
Funding
Abstract
backgroundResearch suggests that fetal exposure to magnesium sulfate before preterm birth might reduce the risk of cerebral palsy.
methodsIn this multicenter, placebo-controlled, double-blind trial, we randomly assigned women at imminent risk for delivery between 24 and 31 weeks of gestation to receive magnesium sulfate, administered intravenously as a 6-g bolus followed by a constant infusion of 2 g per hour, or matching placebo. The primary outcome was the composite of stillbirth or infant death by 1 year of corrected age or moderate or severe cerebral palsy at or beyond 2 years of corrected age.
resultsA total of 2241 women underwent randomization. The baseline characteristics were similar in the two groups. Follow-up was achieved for 95.6% of the children. The rate of the primary outcome was not significantly different in the magnesium sulfate group and the placebo group (11.3% and 11.7%, respectively; relative risk, 0.97; 95% confidence interval [CI], 0.77 to 1.23). However, in a prespecified secondary analysis, moderate or severe cerebral palsy occurred significantly less frequently in the magnesium sulfate group (1.9% vs. 3.5%; relative risk, 0.55; 95% CI, 0.32 to 0.95). The risk of death did not differ significantly between the groups (9.5% vs. 8.5%; relative risk, 1.12; 95% CI, 0.85 to 1.47). No woman had a life-threatening event.
conclusionsFetal exposure to magnesium sulfate before anticipated early preterm delivery did not reduce the combined risk of moderate or severe cerebral palsy or death, although the rate of cerebral palsy was reduced among survivors. (ClinicalTrials.gov number, NCT00014989.)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.